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Declining Morbidity and Mortality among 
Patients with Advanced HIV Infection
Viral load suppression is 
predictive of mortality benefit





Vlahov et al., Prognostic indicators for AIDS and infectious disease death in
HIV-infected injection drug users: plasma viral load and CD4+ cell count. 
JAMA. 1998 Jan 7;279(1):35-40.
HIV Treatment: Controlling concentrations






























Antimicrob Agents Chemother 47: 594-600, 2003
Predictor of Virologic Response to Ritonavir-Amprenavir
in HIV Protease Inhibitor Experienced Patients
Case 1. Tipranavir
Debate at Advisory Committee & Beyond
Sponsor: 500 mg twice daily for everyone 
Vs
Individualize dosing based on trough drug 
concentration & IC50 (IQ)














































TPV Cmin, IC50, T20 co-administration 
significantly influence viral response
For IQ ≥ 100, 54% responded to TPV and 73% responded to TPV+T20
For IQ < 100, 21% responded to TPV and 52% responded to TPV+T20













































phase 3 without T20 (n=200)





















Reasons given for not changing
• Commercial drug assay not available
• IC50 phenotype too expensive (~$700)
• Reimbursement
• Prospective trial needed to test 
hypothesis: HIV protease resistant 
patients benefit from IQ testing
• Implementation variation in clinical 
practice
• Hidden elephant: marketing
Dilemma
• Inside FDA Clinical Pharmacology was 
proposing changes. Clinical Division 
(OND) did not agree in this instance, 
but has agreed to study the issue
• Company did not agree
• How will the issue be resolved?
• How can FDA and clinicians bridge the 
regulatory……clinical gap to treat (e.g., 
dose) individual patients, not 
populations?
What do we really want?
• Patients/Heath Professionals
– Health
– Effective drugs @ affordable cost
• Drug Companies
– ↑ Profits → better drugs & ↑ #
– One dosage regimen for all
• FDA
– Promote public health
– ↑ Productivity (process & very effective drugs) & ↓ toxicity
– Personalized medicine
Outline
• How FDA makes decisions
• High attrition, high cost, low productivity
• Model based drug development
– Disease models
– Modeling & simulation
• People development
Drug Development & Regulator Process            
Overview                  
Late 
Discovery Pre-Clinical Phase I Phase II Phase III
NDAIND
a:Proof of Principle b:Dose Ranging
Develop DECIDESELECT
• IND- application to give drug to 





Key question: is this drug safe to 





•Target product profile strategy
•Dose finding
•NDA-application to market new 
drug, dosage form, indication
•IND information + gene tox + 
carcinogenicity
•Clinical trial evidence of 
efficacy & safety















• Filing Decision 
60 days





6 weeks before 












OND Team Leader (MD)
Office Director (MD) (NCEs)
Therapeutic Division Director (MD) (e.g., Cardiorenal)










Reasons for Poor Decisions
(Definition: an outcome which should/could 
have been anticipated)
• Conspiracy of optimism
• Framing the problem too narrowly to bring it inside 
my own comfort zone
• Not involving the right people
• Avoiding uncertainty
• Ignoring information I do not understand
• Being attached to ‘sunk costs’ – high spent 
development costs 
• Ignoring risks
• Assuming no uncertainty in potential outcomes
• Making decision alone
Hammond, Keeney, Raiffa. Smart Choices Harvard Business School Press, 1999
Causes of Attrition (1991 & 2000)
10 Big PhRMA Companies







1 Driver for Clinical Trial M&S                
Declining Success Across Clinical Phases
Science 309:726, 2005
50% Clinical Trial Failure Rate:
Is it true? What to do?









Account for known 
failure sources (prior 
information) in clinical 
trial design
Case 2: Reducing Disease Biomarker  
Concentration → Lower Risk of Disease 

























LL of 95% CL




























Biomarker level % change relative to baseline
-100%        -50%            0              50%          100%
Placebo + treatment arms
Drug Reduces Biomarker Levels 
(Median)
Study X


































Greater Reduction in Biomarker Level 
Is Required for Significant Benefit

























LL of 95% CL


































• Bm predicts disease                   
exacerbation
• Largest slope
• Bm no change in placebo
• Bm↓ 37% 2°Drug
• n=150/arm
• 22% exacerbation with 
placebo




























Moerman, D. E. et. al. Ann Intern Med 2002;136:471-476
Duodenal Ulcer Healing Rate in Active (Cimetidine or 
Ranitidine) vs Placebo (n=83 studies)
Good luck
Bad luck
Placebo Response in Depression
JAMA 287: 1840-7, 2002
↑ trial failure risk





















IMPACT OPPORTUNITIES- MODEL & SIMULATE KEY DECISIONS
COMPANY → TRIAL DESIGN (2, 3), GO/NO GO, LABELING, FORMULATION, COMBO’S, PEDS
FDA → TRIAL DESIGN (2, 3, 4), NDA APPROVAL (BENEFIT/RISK, DOSING REGIMEN), 
LABELING, APPROVAL CRITERIA (GUIDANCE REVISION), FORMULATION, COMBOS, 











































































• Receptor subtype present?
• Cell, protein, antibody, 
small MW chemical, 
physical measure
• linked to endpoint 






• e.g., antiviral 
protease inhibitors
• PET, MRI,..
• Physical direct evidence 
for change
Modeling & Simulation 
Influences All Lives Today
• Weather forecasting


































• Decrease bias & risk in decisions
• Overcome complexity (simultaneously thinking 
about many factors influencing outcome)






























Case 3. Type 2 Diabetes Drug
• Topic: Phase 3 trial design when 3x 
genotypic drug clearance difference
• UGT2B15 metabolic enzyme frequency 
distribution (N=374)
– *1/*1  21%
– *1/*2  52%            
– *2/*2  27%     Poor metabolizers (PM’s)
• Indication: Type 2 diabetes mellitus
• Mechanism of action: PPARx,y,z agonist
• ↓ FPG & HbA1c
• ↑ weight
Extensive metabolizers (EM’s)
Jaya Vaidyanathan, Hae-Young Ahn, Dong Yim, Jenny Zheng, Yaning Wang, Joga Gobburu, 
Todd Sahlroot, David Orloff
Modeling Strategy
• Pharmacokinetics 
– Phase 1 data for population PK model
– Phase 2 data for model update
• Pharmacodynamics (FPG and HbA1c)
– Model from FDA clinical trial data
– Simultaneous modeling FPG and HbA1c



















































Cmt 1 Cmt 2
1st order Oral Absorption
Diabetes
Bill Jusko’s model
Modeling Results for FPG & HbA1C
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(Genotype 1st, Parallel Dose, Placebo Control)




















HbA1c Change from Baseline at Week 26
(naïve only, no placebo effect)































X bid     2X bid    4X bid    2X qd 4X qd 8X qd
EM (1/1 or 1/2) PM (2/2)
• PM response ~ EM response @ 3X dose
• Dose-response evident
• BID better than QD
Enrichment by Response
Randomize Low Dose Non-Responders (FPG ↓ <1.5 mmol/L)
to Med and High Doses










Simulation 2 Sponsor trials X mg QD
X mg Responders (100%)
Non-Responders (33%)








• Trial Design Strategies:
a) Enrichment by genotype: stratify into 
parallel dose
• Dose selection: X & 2X mg daily doses for 
PM’s are informative (naïve + experienced)
• BID performs better than QD, more so in EM’s
• Sustained release could help
b) Enrichment by response
• Further evaluation by M&S if sponsor is 
interested.
• FDA analysis sent to sponsor
Drug-disease models at FDA








– Vasomotor Symptoms (Hot Flashes)
– SLE-renal flare
– Prostate Cancer- chemical castration
– Kidney transplant rejection
• In Development
– Osteoarthritis
– Non-small cell lung cancer
• Considering
– How to share models & some data on public website. Public 
dialogue on growing models
People
– Attributes











































• Technology & Leadership drive 
opportunity
• Dose-response still important source of 
drug development failure & toxicity 
once drugs are on market
• These problems are real, not abstract & 
provide a great mission for a career
• Impact is education & more
